{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:49:45Z","timestamp":1788587385197,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier","isbn-type":[{"value":"9780323985901","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acc.2022.08.001","type":"book-chapter","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T22:51:35Z","timestamp":1663887095000},"page":"217-263","source":"Crossref","is-referenced-by-count":20,"title":["Drug testing in the era of new psychoactive substances"],"prefix":"10.1016","member":"78","reference":[{"issue":"10","key":"10.1016\/bs.acc.2022.08.001_bb0010","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/clinchem\/39.10.2137","article-title":"Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay and fluorescence polarization immunoassay compared for drugs of abuse screening","volume":"39","author":"Armbruster","year":"1993","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/clinchem\/41.1.92","article-title":"Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening","volume":"41","author":"Armbruster","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0020","series-title":"Clinical Chemistry, Immunology and Laboratory Quality Control","first-page":"25","article-title":"Chapter 2: Immunoassay design and issues of interferences","author":"Dasgupta","year":"2021"},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/clinchem\/19.8.821","article-title":"Homogeneous enzyme immunoassay for opiates in urine","volume":"19","author":"Schneider","year":"1973","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/clinchem\/23.1.116","article-title":"Anticonvulsants in serum, determined with a fully mechanized enzyme analyzer","volume":"23","author":"McClean","year":"1977","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-200404000-00020","article-title":"Detection times of drugs of abuse in blood, urine, and oral fluid","volume":"26","author":"Verstraete","year":"2004","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/bs.acc.2022.08.001_bb0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1520\/JFS14827J","article-title":"Elimination of 7-aminoflunitrazepam and flunitrazepam in urine after a single dose of Rohypnol","volume":"45","author":"Negrusz","year":"2000","journal-title":"J. Forensic. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1309\/LMDNLG1ZVOS2R8TV","article-title":"Choosing the right benzodiazepine assay: Impact on clinical decision making","volume":"41","author":"French","year":"2010","journal-title":"Lab. Med."},{"issue":"1-2","key":"10.1016\/bs.acc.2022.08.001_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2009.05.027","article-title":"Extended urinary delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure","volume":"105","author":"Lowe","year":"2009","journal-title":"Drug Alcohol. Depend."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/15.1.1","article-title":"Forensic drug testing for opiates: I. Detection of 6-monoacetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times","volume":"15","author":"Cone","year":"1991","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0060","series-title":"Critical Issues in Alcohol and Drugs of Abuse Testing","first-page":"121","article-title":"Chapter 9: Immunoassay design for screening of drugs of abuse","author":"Datta","year":"2019"},{"key":"10.1016\/bs.acc.2022.08.001_bb0065","series-title":"Clinical Chemistry, Immunology and Laboratory Quality Control","first-page":"337","article-title":"Chapter 16: Drugs of abuse testing","author":"Dasgupta","year":"2021"},{"issue":"67","key":"10.1016\/bs.acc.2022.08.001_bb0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/clinchem\/hvaa305","article-title":"How can routine clinical laboratories keep up with the opioid crisis?","volume":"30","author":"Snozek","year":"2021","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1373\/jalm.2017.023341","article-title":"Executive summary: american association of clinical chemistry laboratory medicine practice guideline\u2014using clinical laboratory tests to monitor drug therapy in pain management patients","volume":"2","author":"Jannetto","year":"2018","journal-title":"J. Appl. Lab. Med."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13181-010-0131-5","article-title":"Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay","volume":"7","author":"Casey","year":"2011","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cca.2014.09.012","article-title":"Ranitidine interference with standard amphetamine immunoassay","volume":"438","author":"Liu","year":"2015","journal-title":"Clin. Chim. Acta."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0095","first-page":"36","article-title":"False-positive urine screening for benzodiazepines: an association with sertraline? A two-year retrospective chart analysis","volume":"6","author":"Nasky","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/jat\/22.1.50","article-title":"Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine","volume":"22","author":"Fraser","year":"1998","journal-title":"J. Anal. Toxicol."},{"issue":"5","key":"10.1016\/bs.acc.2022.08.001_bb0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jat\/32.5.339","article-title":"Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine","volume":"32","author":"Shaikh","year":"2008","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1258\/acb.2011.011118","article-title":"Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol","volume":"49","author":"Oosthuizen","year":"2012","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0115","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/clinchem\/36.4.602","article-title":"Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs","volume":"36","author":"Rollins","year":"1990","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jat\/bkv081","article-title":"Concentrations of morphine and codeine in paired oral fluid and urine specimens following ingestion of a poppy seed roll and raw poppy seeds","volume":"39","author":"Samano","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.acc.2020.10.001","article-title":"Synthetic drugs of abuse","volume":"103","author":"Tamama","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0130","unstructured":"UNODC, Early Warning Advisory on New Psychoactive Substances, https:\/\/www.unodc.org\/LSS\/Home\/NPS. (accessed 30.03.2022)."},{"key":"10.1016\/bs.acc.2022.08.001_bb0135","unstructured":"World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8), https:\/\/www.unodc.org\/res\/wdr2021\/field\/WDR21_Booklet_2.pdf. (accessed 30.03.2022)."},{"key":"10.1016\/bs.acc.2022.08.001_bb0140","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1002\/jcph.1923","article-title":"Clinical pharmacology, toxicity, and abuse potential of opioids","volume":"61","author":"Vearrier","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/15563650.2017.1339889","article-title":"Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose","volume":"56","author":"Griswold","year":"2018","journal-title":"Clin. Toxicol."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/YCO.0000000000000607","article-title":"Drug checking to detect fentanyl and new psychoactive substances","volume":"33","author":"Palamar","year":"2020","journal-title":"Curr. Opin. Psychiatry."},{"key":"10.1016\/bs.acc.2022.08.001_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1373\/jalm.2017.023028","article-title":"A case of opioid overdose? Or is it?","volume":"2","author":"French","year":"2018","journal-title":"J. Appl. Lab. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/15563650.2013.768344","article-title":"Cross-reactivity studies and predictive modeling of \u201cBath salts\u201d and other amphetamine-type stimulants with amphetamine screening immunoassay","volume":"51","author":"Petrie","year":"2013","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FTD.0000000000000475","article-title":"Lack of detection of new amphetamine-like drugs using conventional urinary immunoassays","volume":"40","author":"Begeman","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.08.001_bb0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-2946-6-22","article-title":"Using cheminformatics to predict cross reactivity of \u201cdesigner drugs\u201d to their currently available immunoassays","volume":"6","author":"Krasowski","year":"2014","journal-title":"J. Cheminform."},{"issue":"5","key":"10.1016\/bs.acc.2022.08.001_bb0185","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/jalm\/jfab033","article-title":"Performance evaluation of an automated fentanyl immunoassay","volume":"6","author":"Tang","year":"2021","journal-title":"J. Appl. Lab. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jat\/bkaa181","article-title":"Detection of 30 fentanyl analogs by commercial immunoassay kits","volume":"45","author":"Wharton","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0195","article-title":"Gunsolus Urine drug screening in the era of designer benzodiazepines: comparison of three immunoassay platforms, LC-QTOF-MS and LC-MS\/MS","author":"Puzyrenko","year":"2021","journal-title":"Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.forsciint.2014.04.020","article-title":"Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine","volume":"241","author":"Barnes","year":"2014","journal-title":"Forensic Sci. Int."},{"issue":"7-8","key":"10.1016\/bs.acc.2022.08.001_bb0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/dta.1633","article-title":"Validation of the only commercially available immunoassay for synthetic cathinones in urine: randox drugs of abuse V biochip array technology","volume":"6","author":"Ellefsen","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/bs.acc.2022.08.001_bb0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.acc.2016.09.003","article-title":"Advances in clinical mass spectrometry","volume":"79","author":"French","year":"2017","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0230","series-title":"Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline. CLSI Document C62-A","author":"CLSI","year":"2014"},{"key":"10.1016\/bs.acc.2022.08.001_bb0235","series-title":"Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline. CLSI Document C50-A","author":"CLSI","year":"2007"},{"issue":"22","key":"10.1016\/bs.acc.2022.08.001_bb0240","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.4155\/bio.13.244","article-title":"The challenges of LC-MS\/MS analysis of opiates and opioids in urine","volume":"5","author":"French","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/bs.acc.2022.08.001_bb0250","series-title":"Mass Spectrometry for the Clinical Laboratory","first-page":"37","article-title":"Chapter 3: Sample preparation techniques for mass spectrometry in the clinical laboratory","author":"Stone","year":"2017"},{"key":"10.1016\/bs.acc.2022.08.001_bb0255","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1039\/c4an00094c","article-title":"Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS\/MS","volume":"139","author":"Bylda","year":"2014","journal-title":"Analyst"},{"issue":"23","key":"10.1016\/bs.acc.2022.08.001_bb0260","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.4155\/bio.11.266","article-title":"Hydrophilic interaction LC-MS\/MS analysis of opioids in urine: significance of glucuronide metabolites","volume":"3","author":"French","year":"2011","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0265","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1373\/jalm.2016.022947","article-title":"Opiate and benzodiazepine confirmations: to hydrolyze or not to hydrolyze","volume":"2","author":"Johnson-Davis","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/bs.acc.2022.08.001_bb0270","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jat\/17.4.208","article-title":"The quantitative conversion of morphine 3-beta-D glucuronide to morphine using beta-glucuronidase obtained from Patella vulgate as compared to acid hydrolysis","volume":"17","author":"Jennison","year":"1993","journal-title":"J. Anal. Toxicol."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0275","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jat\/29.7.704","article-title":"Direct analysis of opiates in urine by liquid chromatography-tandem mass spectrometry","volume":"29","author":"Edinboro","year":"2005","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-61779-934-1_9","article-title":"Quantitation of amphetamine-type stimulants by LC-MS\/MS","volume":"902","author":"Middleberg","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0285","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jat\/32.7.491","article-title":"Quantitation of benzodiazepines in urine, serum, plasma and meconium by LC-MS\/MS","volume":"32","author":"Marin","year":"2008","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-61779-934-1_8","article-title":"Cocaine and metabolites by LC-MS\/MS","volume":"902","author":"Snozek","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0295","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-60761-459-3_40","article-title":"Quantitation of morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone and 6-monoacetylmorphine (6-MAM) in urine, blood, serum or plasma using liquid chromatography with tandem mass spectrometry detection","volume":"603","author":"Dahn","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0300","first-page":"41","article-title":"Targeted opioid screening assay for pain management using high-resolution mass spectrometry","volume":"2019","author":"Danso","year":"1872","journal-title":"Methods. Mol. Biol."},{"issue":"6","key":"10.1016\/bs.acc.2022.08.001_bb0305","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcpt.13519","article-title":"Veenstra LC-MS-sMRM method development and validation of different classes of pain panel drugs and analysis of clinical urine samples","volume":"127","author":"Masood","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/bs.acc.2022.08.001_bb0310","first-page":"E583","article-title":"Clinical benefits of direct-to-definitive testing for monitoring compliance in pain management","volume":"21","author":"Gencheva","year":"2018","journal-title":"Pain Physician."},{"key":"10.1016\/bs.acc.2022.08.001_bb0315","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4939-3252-8_24","article-title":"Quantitative, multidrug pain medication testing by liquid chromatography: tandem mass spectrometry (LC-MS\/MS)","volume":"1383","author":"Bodor","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"13","key":"10.1016\/bs.acc.2022.08.001_bb0325","first-page":"158","article-title":"Lee Simultaneous screening of 177 drugs of abuse in urine using ultra-performance liquid chromatography with tandem mass spectrometry in drug-intoxicated patients","volume":"11","author":"Y-W.","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"15","key":"10.1016\/bs.acc.2022.08.001_bb0330","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.clinbiochem.2009.07.019","article-title":"Drugs of abuse testing by mass spectrometry: a rapid, simple method to replace immunoassays","volume":"42","author":"Eichhorst","year":"2009","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jalm\/jfab157","article-title":"Development and implementation of a one-step, broad-spectrum, high-sensitivity drug screening by tandem mass spectrometry in a pediatric population","volume":"7","author":"Tesfazghi","year":"2022","journal-title":"J. Appl. Lab. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0340","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jalm\/jfab172","article-title":"Is the best drug test the enemy of the good STAT toxicology screen?","volume":"7","author":"Stone","year":"2022","journal-title":"J. Appl. Lab. Med."},{"issue":"9","key":"10.1016\/bs.acc.2022.08.001_bb0345","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4155\/bio.15.48","article-title":"Detection and quantitation of 56 new psychoactive substances in whole blood and urine by LC-MS\/MS","volume":"7","author":"Ambach","year":"2015","journal-title":"Bioanalysis"},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0350","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jat\/bkaa103","article-title":"A comprehensive HPLC-Ms-MS screening method for 77 new psychoactive substances, 24 classic drugs and 18 related metabolites in blood, urine and oral fluid","volume":"44","author":"Di Trana","year":"2020","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0355","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/dta.2680","article-title":"Solid-phase extraction-liquid chromatography-tandem mass spectrometry method for the qualitative analysis of 61 synthetic cannabinoid metabolites in urine","volume":"12","author":"Gaunitz","year":"2020","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0360","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/add.13056","article-title":"The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015","volume":"111","author":"Mounteney","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/bs.acc.2022.08.001_bb0365","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/164_2017_83","article-title":"Bioanalytical methods for new psychoactive substances","volume":"252","author":"Wagmann","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0370","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0375","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\"Zombie\" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13-14","key":"10.1016\/bs.acc.2022.08.001_bb0380","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2016.07.010","article-title":"Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology\u2014an update","volume":"49","author":"Remane","year":"2016","journal-title":"Clin. Biochem."},{"issue":"9","key":"10.1016\/bs.acc.2022.08.001_bb0385","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00216-020-03064-y","article-title":"Hyphenated high-resolution mass spectrometry-the \"all-in-one\" device in analytical toxicology?","volume":"413","author":"Maurer","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"issue":"25","key":"10.1016\/bs.acc.2022.08.001_bb0390","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1007\/s00216-017-0441-4","article-title":"Current applications of high-resolution mass spectrometry for the analysis of new psychoactive substances: a critical review","volume":"409","author":"Pasin","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0395","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/ac203191t","article-title":"High resolution mass spectrometry","volume":"84","author":"Xian","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0400","unstructured":"M.P. Balogh, Debating Resolution and Mass Accuracy in Mass Spectrometry. (2004). https:\/\/www.semanticscholar.org\/paper\/Debating-Resolution-and-Mass-Accuracy-Balogh\/6333d74b2eac8f3752ab7b9690467913895ffb6a. (accessed 31.03.2022)."},{"issue":"4","key":"10.1016\/bs.acc.2022.08.001_bb0405","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/15563650.2016.1139714","article-title":"Non-targeted screening for novel psychoactive substances among agitated emergency department patients","volume":"54","author":"Lung","year":"2016","journal-title":"Clin. Toxicol. (Phila)."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0410","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/add.14808","article-title":"The psychoactive surveillance consortium and analysis network (PSCAN): the first year","volume":"115","author":"Monte","year":"2020","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0415","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bcp.14115","article-title":"Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication","volume":"83","author":"Grafinger","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0420","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.aca.2017.03.002","article-title":"Liquid chromatography-high resolution-tandem mass spectrometry using orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma","volume":"965","author":"Helfer","year":"2017","journal-title":"Anal. Chim. Acta."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0425","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.kjms.2016.01.007","article-title":"Simultaneous identification of abused drugs, benzodiazepines, and new psychoactive substances in urine by liquid chromatography tandem mass spectrometry","volume":"32","author":"Lee","year":"2016","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0430","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jssc.201801249","article-title":"Determination of several synthetic cathinones and an amphetamine-like compound in urine by gas chromatography with mass spectrometry. method validation and application to real cases","volume":"42","author":"Gerace","year":"2019","journal-title":"J. Sep. Sci."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0435","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/dta.2508","article-title":"Suspect and non-target screening workflows to investigate the in vitro and in vivo metabolism of the synthetic cannabinoid 5Cl-THJ-018","volume":"11","author":"Vervliet","year":"2019","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0440","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/FTD.0b013e3181dca295","article-title":"Perspectives of liquid chromatography coupled to low- and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology","volume":"32","author":"Maurer","year":"2010","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0445","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/15563650.2012.713108","article-title":"Role of liquid chromatography-high-resolution mass spectrometry (LC-HR\/MS) in clinical toxicology","volume":"50","author":"Wu","year":"2012","journal-title":"Clin. Toxicol. (Phila)."},{"key":"10.1016\/bs.acc.2022.08.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110274","article-title":"Retrospective screening of synthetic cannabinoids, synthetic opioids and designer benzodiazepines in data files from forensic post mortem samples analysed by UHPLC-QTOF-MS from 2014 to 2018","volume":"311","author":"Gundersen","year":"2020","journal-title":"Forensic Sci. Int."},{"issue":"2","key":"10.1016\/bs.acc.2022.08.001_bb0455","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/dta.2744","article-title":"Pitfalls in drug testing by hyphenated low- and high-resolution mass spectrometry","volume":"12","author":"Maurer","year":"2020","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0460","doi-asserted-by":"crossref","first-page":"135","DOI":"10.33176\/AACB-19-00023","article-title":"Quadrupole time-of-flight mass spectrometry: a paradigm shift in toxicology screening applications","volume":"40","author":"Allen","year":"2019","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/bs.acc.2022.08.001_bb0465","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1007\/s00216-016-9521-0","article-title":"Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry","volume":"408","author":"Gonz\u00e1lez-Mari\u00f1o","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"issue":"6","key":"10.1016\/bs.acc.2022.08.001_bb0470","first-page":"592","article-title":"Sensitive screening of new psychoactive substances in serum using liquid-chromatography quadrupole time-of-flight mass spectrometry","volume":"46","author":"Kleis","year":"2021","journal-title":"J. Anal."},{"key":"10.1016\/bs.acc.2022.08.001_bb0475","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.trac.2015.12.019","article-title":"Current status of non-targeted liquid chromatography-tandem mass spectrometry in forensic toxicology","volume":"84","author":"Oberacher","year":"2016","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0480","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1007\/s00216-015-8681-7","article-title":"Non-target screening with high-resolution mass spectrometry: critical review using a collaborative trial on water analysis","volume":"407","author":"Schymanski","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0485","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00216-010-3608-9","article-title":"LC-high resolution MS in environmental analysis: from target screening to the identification of unknowns","volume":"397","author":"Krauss","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0490","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/15563650.2014.933231","article-title":"Comprehensive analysis of \"bath salts\" purchased from California stores and the internet","volume":"52","author":"Schneir","year":"2014","journal-title":"Clin. Toxicol. (Phila)."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0495","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jat\/bks084","article-title":"Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens","volume":"37","author":"Guale","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0500","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.chroma.2016.07.062","article-title":"Analysis of psychoactive substances in water by information dependent acquisition on a hybrid quadrupole time-of-flight mass spectrometer","volume":"1461","author":"Andr\u00e9s-Costa","year":"2016","journal-title":"J. Chromatogr. A."},{"issue":"1-3","key":"10.1016\/bs.acc.2022.08.001_bb0505","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.forsciint.2011.10.004","article-title":"General unknown screening in hair by liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry (LC-QTOF-MS)","volume":"218","author":"Broecker","year":"2012","journal-title":"Forensic Sci. Int."},{"issue":"15","key":"10.1016\/bs.acc.2022.08.001_bb0510","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1007\/s00216-013-7574-x","article-title":"LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine","volume":"406","author":"Kronstrand","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"issue":"5","key":"10.1016\/bs.acc.2022.08.001_bb0515","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/dta.2043","article-title":"Multi-class analysis of new psychoactive substances and metabolites in hair by pressurized liquid extraction coupled to HPLC-HRMS","volume":"9","author":"Montesano","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0520","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/dta.2464","article-title":"Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS","volume":"11","author":"Gundersen","year":"2019","journal-title":"Drug Test. Anal."},{"issue":"10","key":"10.1016\/bs.acc.2022.08.001_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.9067","volume":"35","author":"Kim","year":"2021","journal-title":"Rapid. Commun. Mass Spectrom."},{"issue":"8","key":"10.1016\/bs.acc.2022.08.001_bb0530","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/dta.3052","article-title":"Sensitive screening of synthetic cannabinoids using liquid chromatography quadrupole time-of-flight mass spectrometry after solid phase extraction","volume":"13","author":"Kleis","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"21","key":"10.1016\/bs.acc.2022.08.001_bb0535","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1007\/s00216-021-03533-y","article-title":"Simultaneous determination of 137 drugs of abuse, new psychoactive substances, and novel synthetic opioids in meconium by UHPLC-QTOF","volume":"413","author":"L\u00f3pez-Rabu\u00f1al","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0540","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinbiochem.2021.05.004","article-title":"Urine toxicology screening by liquid chromatography time-of-flight mass spectrometry in a quaternary hospital setting","volume":"95","author":"Pope","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2022.08.001_bb0545","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1007\/s00216-015-9036-0","article-title":"A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples","volume":"407","author":"Kinyua","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"7","key":"10.1016\/bs.acc.2022.08.001_bb0550","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/dta.2120","article-title":"Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition","volume":"9","author":"Mollerup","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/bs.acc.2022.08.001_bb0555","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.scitotenv.2016.08.124","article-title":"Qualitative screening of new psychoactive substances in pooled urine samples from Belgium and United Kingdom","volume":"573","author":"Kinyua","year":"2016","journal-title":"Sci. Total Environ."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0560","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/dta.1818","article-title":"Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS","volume":"8","author":"Sundstr\u00f6m","year":"2016","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0565","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00216-014-8118-8","article-title":"Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry","volume":"407","author":"Scheidweiler","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"10","key":"10.1016\/bs.acc.2022.08.001_bb0570","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3109\/15563650.2015.1100306","article-title":"An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA","volume":"53","author":"Tyndall","year":"2015","journal-title":"Clin. Toxicol. (Phila)."},{"issue":"5","key":"10.1016\/bs.acc.2022.08.001_bb0575","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jemermed.2014.12.038","article-title":"A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA","volume":"48","author":"Schwartz","year":"2015","journal-title":"J. Emerg. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.08.001_bb0580","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/15563650.2018.1485927","article-title":"Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015)","volume":"57","author":"Kasper","year":"2019","journal-title":"Clin. Toxicol. (Phila)."},{"key":"10.1016\/bs.acc.2022.08.001_bb0585","series-title":"DEA TOX: Quarterly Report\u20144th Quarter 2021","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2021"},{"key":"10.1016\/bs.acc.2022.08.001_bb0590","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2018_160","article-title":"Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures","volume":"253","author":"Evans-Brown","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/bs.acc.2022.08.001_bb0595","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jat\/bkz084","article-title":"Emerging synthetic cannabinoids: development and validation of a novel liquid chromatography quadrupole time-of-flight mass spectrometry assay for real-time detection","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2022.08.001_bb0600","series-title":"DEA TOX: Quarterly Report\u20141st Quarter 2021","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2021"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T07:56:58Z","timestamp":1753689418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323985901"],"references-count":113,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.08.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}